State of the art on TTP
Presenter: Dr. Spero Cataland
Dr. Spero Cataland is a Professor of Internal Medicine in the Division of Hematology at the Wexner Medical Center at the Ohio State University City. He is also the co-director of the Benign Hematology Program at Ohio State University and the Director of Research. Dr. Cataland received his medical degree from Ohio State University College of Medicine and completed his residency at Ohio State University Hospital, after which he went on to hold a fellowship in hematology/oncology at the University of Chicago Medical Center. After completing his training in hematology he returned to Ohio State University where he presently remains on the faculty.
Dr. Cataland's clinical and research interests include thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uremic syndrome (aHUS) with an emphasis on acquired TTP. Dr. Cataland directs the Biomarker Reference Laboratory at Ohio State University that performs correlative laboratory studies for ongoing research projects and also serves as a reference lab for several ongoing clinical trials. Dr. Cataland has a longstanding interest in novel therapeutic approaches to acquired TTP as well as ongoing research emphasis to better understand the development of long-term complications in patients with a prior history of TTP and the mechanisms for their development. Dr. Cataland has also worked to establish the United States Thrombotic Microangiopathy Clinical Consortium, an organization of 15 academic medical centers across the United States that was organized for the purposes of conducting collaborative research in TTP and atypical haemolytic uremic syndrome.
